CD53 and osteosarcoma: In 2005, the earliest study has been performed to assay the validity and usefulness in clinics of an immunomagnetic method for detection of tumor cells in bone marrow (BM) and peripheral blood (PB) of patients with osteosarcoma, through testing of two osteosarcoma-associated antigens, namely a cell surface antigen with homology to the bone isoenzyme of alkaline phosphatase and the high molecular weight melanoma-associated antigen 9.2.27 [178].